First Alzheimer's patients test new brain drug
NCT ID NCT06814730
Summary
This early-stage study is testing whether a new drug called THN391 is safe for people with early Alzheimer's disease. Fifteen participants aged 65-85 will receive either the drug or a placebo injection three times over two months, followed by four months of monitoring. Researchers will check for side effects and measure how much of the drug gets into the bloodstream and spinal fluid using blood tests, brain scans, and spinal taps.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, EARLY ONSET are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, New Hampshire, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CTC-Netherlands
RECRUITINGGroningen, 9713 EZ, Netherlands
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scottish Brain Sciences
RECRUITINGEdinburgh, EH12 9DQ, United Kingdom
Contact Email: •••••@•••••
Contact
-
University College London Hospitals
RECRUITINGLondon, WC1N 3BG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.